Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
SUN PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
SUN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,072 | 3,479 | - | |
Low | Rs | 790 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 182.9 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 35.7 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 46.2 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 11.50 | 109.18 | - | |
Avg Dividend yield | % | 1.2 | 3.4 | 36.8% | |
Book value per share (Unadj.) | Rs | 233.4 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 2,399.34 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.1 | 1.6 | 312.6% | |
Avg P/E ratio | x | 26.1 | 26.1 | 100.1% | |
P/CF ratio (eoy) | x | 20.1 | 11.4 | 177.3% | |
Price / Book Value ratio | x | 4.0 | 1.5 | 272.1% | |
Dividend payout | % | 32.2 | 87.5 | 36.8% | |
Avg Mkt Cap | Rs m | 2,233,361 | 2,756,220 | 81.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 82,960 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 438,857 | 1,692,969 | 25.9% | |
Other income | Rs m | 8,199 | 0 | - | |
Total revenues | Rs m | 447,055 | 1,692,969 | 26.4% | |
Gross profit | Rs m | 112,900 | 463,620 | 24.4% | |
Depreciation | Rs m | 25,294 | 136,844 | 18.5% | |
Interest | Rs m | 1,720 | 33,253 | 5.2% | |
Profit before tax | Rs m | 94,084 | 293,523 | 32.1% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 8,476 | -3,584 | -236.5% | |
Profit after tax | Rs m | 85,608 | 105,758 | 80.9% | |
Gross profit margin | % | 25.7 | 27.4 | 93.9% | |
Effective tax rate | % | 9.0 | -1.2 | -737.9% | |
Net profit margin | % | 19.5 | 6.2 | 312.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 398,619 | 1,143,425 | 34.9% | |
Current liabilities | Rs m | 199,064 | 997,163 | 20.0% | |
Net working cap to sales | % | 45.5 | 8.6 | 526.3% | |
Current ratio | x | 2.0 | 1.1 | 174.6% | |
Inventory Days | Days | 147 | 91 | 161.9% | |
Debtors Days | Days | 95 | 96 | 99.2% | |
Net fixed assets | Rs m | 376,960 | 552,961 | 68.2% | |
Share capital | Rs m | 2,399 | 4,167 | 57.6% | |
Net worth | Rs m | 559,954 | 1,880,567 | 29.8% | |
Long term debt | Rs m | 0 | 865,653 | 0.0% | |
Total assets | Rs m | 775,794 | 3,868,976 | 20.1% | |
Interest coverage | x | 55.7 | 9.8 | 566.8% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 129.3% | |
Return on assets | % | 11.3 | 3.6 | 313.3% | |
Return on equity | % | 15.3 | 5.6 | 271.9% | |
Return on capital | % | 17.1 | 4.9 | 346.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 49,593 | 269,772 | 18.4% | |
From Investments | Rs m | -79,437 | -95,591 | 83.1% | |
From Financial Activity | Rs m | 23,761 | -323,609 | -7.3% | |
Net Cashflow | Rs m | 1,155 | -149,429 | -0.8% |
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare SUN PHARMA With: SYNCOM FORMULATIONS MEDICO REMEDIES GRANULES INDIA PARMAX PHARMA SUVEN PHARMACEUTICALS
Indian share markets continued the momentum as the session progressed and ended the higher.